Dr. Reddy's Expands European Operations

Article

Dr. Reddy’s has expanded its commercial operations in Europe with the introduction of its range of generic drugs in France.

Dr. Reddy’s Laboratories has expanded its commercial operations in Europe with the introduction of its range of generic drugs in France. The first products, which include cancer drugs, anti-infectives, and antimycotics, will be made available in the hospital market in March 2017.

The company also recently launched select products of its hospital portfolio in Italy and Spain, and is looking to expand its business in these regions with the launch of anti-HIV products this year.

Dr. Reddy’s has a portfolio of injectables and complex generic drugs. The company currently has two R&D centres, one manufacturing, and a packaging and storage facility in Europe.

Source: Dr. Reddy’s

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content